



-  The global leading on-site nucleic acid testing device
-  Concluding test results 2 days earlier than antigen tests
-  Comprehensive application, expandable for multi-variants detection



Mini Dock

COVID-19
Nucleic Acid Testing System

98.91% Sensitivity, 99.58% Specificity



Clinically Proven

In individual clinical studies of personnel who have COVID-19 symptoms and asymptomatic infected, Pluslife Mini Dock achieved an accurate detection rate that comparable to qPCR nucleic acid detection, presenting exceptional sensitivity and specificity.

Data of the Comparative Clinical Studies

Pluslife	RT-PCR		Total
	Positive	Negative	
Positive	true positive (TP) 181	false positive (FP) 0	TP+FP 181
Negative	false negative (FN) 2	true negative (TN) 70	FN+TN 72
Total	TP+FN 183	FP+TN 70	253


98.91% Sensitivity, 99.58% Specificity

According to the clinical comparative study performed in IlexLab, the Institute of Clinical Research in Israel on February, the molecular detection system from Pluslife achieves identical results comparing to RT-PCR.

Comparison between Pluslife and Antigen Tests

Pluslife Mini Dock has consistent capacity for detecting targets with 400 copies/ml of SARS-CoV-2 virus, achieving much higher sensitivity than the antigen tests. According to the load of the virus in the body, the virus can be detected nearly 2 days in advance comparing to antigen tests and the infection can be detected in time to prevent further outbreak.

Testing Method	Manufacturer	Performances
Nucleic Acid Test	Pluslife	Effectively detect sample with Ct-value reached 44.8
Antigen Test	122 Products from different producers	85% of the products miss all the sample with Ct >30 (Scheiblaue H, 2021)



Killingley B, 2022



Clinically Proven

In individual clinical studies of personnel who have COVID-19 symptoms and asymptomatic infected, Pluslife Mini Dock achieved an accurate detection rate that comparable to qPCR nucleic acid detection, presenting exceptional sensitivity and specificity.

Data of the Comparative Clinical Studies

Pluslife	RT-PCR		Total
	Positive	Negative	
Positive	true positive (TP) 181	false positive (FP) 0	TP+FP 181
Negative	false negative (FN) 2	true negative (TN) 70	FN+TN 72
Total	TP+FN 183	FP+TN 70	253


98.91% Sensitivity, 99.58% Specificity

According to the clinical comparative study performed in IlexLab, the Institute of Clinical Research in Israel on February, the molecular detection system from Pluslife achieves identical results comparing to RT-PCR.

Comparison between Pluslife and Antigen Tests


Pluslife Mini Dock has consistent capacity for detecting targets with 400 copies/ml of SARS-CoV-2 virus, achieving much higher sensitivity than the antigen tests. According to the load of the virus in the body, the virus can be detected nearly 2 days in advance comparing to antigen tests and the infection can be detected in time to prevent further outbreak.

Testing Method	Manufacturer	Performances
Nucleic Acid Test	Pluslife	Effectively detect sample with Ct-value reached 44.8
Antigen Test	122 Products from different producers	85% of the products miss all the sample with Ct >30 (Scheiblaue H, 2021)



Killingly B, 2022

Operating Procedures



Website



Video



LinkedIn



Line

Guangzhou Pluslife Biotech Co.,Ltd

⌚ Floor 3, Block E, Runhui Science & Technology Park, No. 18 Shenzhou RD, Huangpu District, Guangzhou, Guangdong, China

✉ market@pluslife.com

🌐 www.pluslife.com

☎ +86-20-31703986